CFTR modulator therapies in pediatric cystic fibrosis: focus on ivacaftor

References

• Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352(19):1992–2001.
   PubMed Web of Science ®Google Scholar
• Pilewski JM, Frizzell RA. Role of CFTR in airway disease. Physiol Rev. 1999;79(1 Suppl):S215–S255.
   Google Scholar
• Foundation NACF. 2013 North American CFF annual data report to center directors. 2013. Available from: https://www.cff.org/2013_CFF_Annual_Data_Report_to_the_Center_Directors.pdf
   Google Scholar
• North American Cystic Fibrosis Foundation. 2013 North American CFF annual data report to center directors. 2013. Available from: https://www.cff.org/2013_CFF_Annual_Data_Report_to_the_Center_Directors.pdf
   Google Scholar
• CFF, Johns Hopkins Medicine. CFTR2 database. 2015. Available from: www.cftr2.org
   Google Scholar
• Schweibert EM, Benos DJ, Egan ME, et al. CFTR is a conductance regulator as well as a chloride channel. Physiol Rev. 1999;79(S1):S145–S166.
   Google Scholar
• Hudson VM. Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Free Radic Biol Med. 2001;30(12):1440–1461.
   PubMed Web of Science ®Google Scholar
• Moskwa P, Lorentzen D, Excoffon KJDA, et al. A novel host defense system of airways is defective in cystic fibrosis. Am J Respir Crit Care Med. 2007;175(2):174–183.
   PubMed Web of Science ®Google Scholar
• Park M, Ko SBH, Choi JY, et al. The cystic fibrosis transmembrane conductance regulator interacts with and regulates the activity of the HCO3- salvage transporter human Na+-HCO3- cotransport isoform 3. J Biol Chem. 2002;277(52):50503–50509.
   PubMed Web of Science ®Google Scholar
• Anderson MP, Gregory RJ, Thompson S, et al. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science. 1991;253(5016):202–205.
   PubMed Web of Science ®Google Scholar
• Engelhardt JF, Yankaskas JR, Ernst SA, et al. Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat Genet. 1992;2(3):240–248.
   PubMed Web of Science ®Google Scholar
• Engelhardt JF, Zepeda M, Cohn JA, et al. Expression of the cystic fibrosis gene in adult human lung. J Clin Invest. 1994;93(2):737–749.
   PubMed Web of Science ®Google Scholar
• Cohn JA, Strong TV, Picciotto MR, et al. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology. 1993;105(6):1857–1864.
   PubMed Web of Science ®Google Scholar
• Grubb BR, Gabriel SE. Intestinal physiology and pathology in gene-targeted mouse models of cystic fibrosis. Am J Physiol. 1997;273(2 Pt 1):G258–66.
   Google Scholar
• Marino CR, Matovcik LM, Gorelick FS, et al. Localization of the cystic fibrosis transmembrane conductance regulator in pancreas. J Clin Invest. 1991;88(2):712–716.
   PubMed Web of Science ®Google Scholar
• Meyerholz DK, Stoltz DA, Namati E, et al. Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children. Am J Respir Crit Care Med. 2010;182(10):1251–1261.
   PubMed Web of Science ®Google Scholar
• Patrizio P, Asch RH, Handelin B, et al. Aetiology of congenital absence of vas deferens: genetic study of three generations. Hum Reprod. 1993;8(2):215–220.
   PubMed Web of Science ®Google Scholar
• Reddy MM, Bell CL, Quinton PM. Cystic fibrosis affects specific cell type in sweat gland secretory coil. Am J Physiol. 1997;273(2 Pt 1):C426–33.
   Google Scholar
• Stoltz DA, Rokhlina T, Ernst SE, et al. Intestinal CFTR expression alleviates meconium ileus in cystic fibrosis pigs. J Clin Invest. 2013;123(6):2685–2693.
   PubMed Web of Science ®Google Scholar
• Joo NS, Irokawa T, Wu JV, et al. Absent secretion to vasoactive intestinal peptide in cystic fibrosis airway glands. J Biol Chem. 2002;277(52):50710–50715.
   PubMed Web of Science ®Google Scholar
• Wu JV, Krouse ME, Wine JJ. Acinar origin of CFTR-dependent airway submucosal gland fluid secretion. American Journal of Physiology Lung Cellular and Molecular Physiology. 2007;292(1):L304–11.
   Google Scholar
• Joo NS, Irokawa T, Robbins RC, et al. Hyposecretion, not hyperabsorption, is the basic defect of cystic fibrosis airway glands. J Biol Chem. 2006;281(11):7392–7398.
   PubMed Web of Science ®Google Scholar
• Joo NS, Lee DJ, Winges KM, et al. Regulation of antiprotease and antimicrobial protein secretion by airway submucosal gland serous cells. J Biol Chem. 2004;279(37):38854–38860.
   PubMed Web of Science ®Google Scholar
• Choi JY, Joo NS, Krouse ME, et al. Synergistic airway gland mucus secretion in response to vasoactive intestinal peptide and carbachol is lost in cystic fibrosis. J Clin Invest. 2007;117(10):3118–3127.
   PubMed Web of Science ®Google Scholar
• Wine JJ, Joo NS. Submucosal glands and airway defense. Proc Am Thorac Soc. 2004;1(1):47–53.
   PubMedGoogle Scholar
• Chen JH, Stoltz DA, Karp PH, et al. Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. Cell. 2010;143(6):911–923.
   PubMed Web of Science ®Google Scholar
• Hoegger MJ, Fischer AJ, McMenimen JD, et al. Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. Science. 2014;345(6198):818–822.
   PubMed Web of Science ®Google Scholar
• Quinton PM. Role of epithelial HCOFormula transport in mucin secretion: lessons from cystic fibrosis. Am J Physiol Cell Physiol. 2010;299(6):C1222–C1233.
   PubMed Web of Science ®Google Scholar
• Quinton PM. The neglected ion: HCO3. Nat Med. 2001;7(3):292–293.
   PubMed Web of Science ®Google Scholar
• Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet. 2008;372(9636):415–417.
   PubMed Web of Science ®Google Scholar
• Ehre C, Ridley C, Thornton DJ. Cystic fibrosis: an inherited disease affecting mucin-producing organs. Int J Biochem Cell Biol. 2014;52:136–145.
   PubMed Web of Science ®Google Scholar
• Yang N, Garcia MAS, Quinton PM. Normal mucus formation requires cAMP-dependent HCO3- secretion and Ca2+-mediated mucin exocytosis. J Physiol. 2013;591(18):4581–4593.
   PubMed Web of Science ®Google Scholar
• Gray T, Coakley R, Hirsh A, et al. Regulation of MUC5AC mucin secretion and airway surface liquid metabolism by IL-1beta in human bronchial epithelia. Am J Physiol Lung Cell Mol Physiol. 2004;286(2):L320–30.
   Google Scholar
• Kesimer M, Ehre C, Burns KA, et al. Molecular organization of the mucins and glycocalyx underlying mucus transport over mucosal surfaces of the airways. Mucosal Immunol. 2013;6(2):379–392.
   PubMed Web of Science ®Google Scholar
• Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med. 2007;261(1):5–16.
   PubMed Web of Science ®Google Scholar
• Matsui H, Randell SH, Peretti SW, et al. Coordinated clearance of periciliary liquid and mucus from airway surfaces. J Clin Investig. 1998;102(6):1125–1131.
   PubMed Web of Science ®Google Scholar
• Boucher RC. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med. 2007;58:157–170.
   PubMed Web of Science ®Google Scholar
• Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006;354(3):241–250.
   PubMed Web of Science ®Google Scholar
• Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol. 1997;24(2):137–142; discussion 59–61.
   PubMed Web of Science ®Google Scholar
• Chmiel JF, Konstan MW. Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med. 2007;28(2):331–346.
   PubMed Web of Science ®Google Scholar
• Cohen-Cymberknoh M, Kerem E, Ferkol T, et al. Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications. Thorax. 2013;68(12):1157–1162.
   PubMed Web of Science ®Google Scholar
• Sly PD, Gangell CL, Chen L, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med. 2013;368(21):1963–1970.
   PubMed Web of Science ®Google Scholar
• Castellani C, Massie J, Sontag M, et al. Newborn screening for cystic fibrosis. Lancet Respir Med. 2016;4(8):653–651.
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663–1672.
   PubMed Web of Science ®Google Scholar
• Boyle MP, De Boeck K. A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet Respir Med. 2013;1(2):158–163.
   PubMed Web of Science ®Google Scholar
• McKone EF, Emerson SS, Edwards KL, et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet. 2003;361(9370):1671–1676.
   PubMed Web of Science ®Google Scholar
• Van Goor F, Hadida S, Grootenhuis PDJ, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009;106(44):18825–18830.
   PubMed Web of Science ®Google Scholar
• McKone EF, Borowitz D, Drevinek P, et al. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir Med. 2014;2(11):902–910.
   PubMed Web of Science ®Google Scholar
• Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013;187(11):1219–1225.
   PubMed Web of Science ®Google Scholar
• Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010;363(21):1991–2003.
   PubMed Web of Science ®Google Scholar
• Davies JC, Cunningham S, Harris WT, et al. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med. 2016;4(2):107–115.
   PubMed Web of Science ®Google Scholar
• De Boeck K, Munck A, Walker S, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros. 2014;13(6):674–680.
   PubMed Web of Science ®Google Scholar
• Moss RB, Flume PA, Elborn JS, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 2015;3(7):524–533.
   PubMed Web of Science ®Google Scholar
• Sawicki GS, McKone EF, Pasta DJ, et al. Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am J Respir Crit Care Med. 2015;192(7):836–842.
   PubMed Web of Science ®Google Scholar
• Accurso FJ, Van Goor F, Zha J, et al. Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data. J Cyst Fibros. 2014;13(2):139–147.
   PubMed Web of Science ®Google Scholar
• Rowe SM, Heltshe SL, Gonska T, et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med. 2014;190(2):175–184.
   PubMed Web of Science ®Google Scholar
• Durmowicz AG, Witzmann KA, Rosebraugh CJ, et al. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. Chest. 2013;143(1):14–18.
   PubMed Web of Science ®Google Scholar
• Bernarde C, Keravec M, Mounier J, et al. Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation. PLoS One. 2015;10(4):e0124124.
   Google Scholar
• Heltshe SL, Mayer-Hamblett N, Burns JL, et al. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect Dis. 2015;60(5):703–712.
   PubMed Web of Science ®Google Scholar
• Reznikov LR, Abou Alaiwa MH, Dohrn CL, et al. Antibacterial properties of the CFTR potentiator ivacaftor. J Cyst Fibros. 2014;13(5):515–519.
   PubMed Web of Science ®Google Scholar
• Borowitz D, Lubarsky B, Wilschanski M, et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation after treatment with ivacaftor. Dig Dis Sci. 2016;61(1):198–207.
   PubMed Web of Science ®Google Scholar
• Brumback LC, Baines A, Ratjen F, et al. Pulmonary exacerbations and parent-reported outcomes in children <6 years with cystic fibrosis. Pediatr Pulmonol. 2014;50(3):236–243.
   PubMedGoogle Scholar
• Amin R, Subbarao P, Jabar A, et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax. 2010;65(5):379–383.
   PubMed Web of Science ®Google Scholar
• Thomen RP, Walkup LL, Roach DJ, et al. Hyperpolarized 129Xe for investigation of mild cystic fibrosis lung disease in pediatric patients. J Cyst Fibros. 2016. doi:10.1016/j.jcf.2016.07.008. [Epub ahead of print]
   PubMedGoogle Scholar
• Davies J, Sheridan H, Bell N, et al. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. Lancet Respir Med. 2013;1(8):630–638.
   PubMed Web of Science ®Google Scholar
• Thauvin-Robinet C, Munck A, Huet F, et al. The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening. J Med Genet. 2009;46(11):752–758.
   PubMed Web of Science ®Google Scholar
• Chu CS, Trapnell BC, Murtagh JJ, et al. Variable deletion of exon 9 coding sequences in cystic fibrosis transmembrane conductance regulator gene mRNA transcripts in normal bronchial epithelium. EMBO J. 1991;10(6):1355–1363.
   PubMed Web of Science ®Google Scholar
• Chu CS, Trapnell BC, Curristin S, et al. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet. 1993;3(2):151–156.
   PubMed Web of Science ®Google Scholar
• Char JE, Wolfe MH, Cho HJ, et al. A little CFTR goes a long way: CFTR-dependent sweat secretion from G551D and R117H-5T cystic fibrosis subjects taking ivacaftor. PLoS One. 2014;9(2):e88564.
   PubMed Web of Science ®Google Scholar
• Sheikh SI, Long FR, McCoy KS, et al. Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation. J Cyst Fibros. 2015;14(1):84–89.
   PubMed Web of Science ®Google Scholar
• Sheikh SI, Long FR, McCoy KS, et al. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation. Clin Otolaryngol. 2015;40(1):16–21.
   PubMed Web of Science ®Google Scholar
• Flors L, Mugler JP 3rd, de Lange EE, et al. Hyperpolarized gas magnetic resonance lung imaging in children and young adults. J Thorac Imaging. 2016;31(5):285–295.
   PubMed Web of Science ®Google Scholar
• Bannier E, Cieslar K, Mosbah K, et al. Hyperpolarized 3He MR for sensitive imaging of ventilation function and treatment efficiency in young cystic fibrosis patients with normal lung function. Radiology. 2010;255(1):225–232.
   PubMed Web of Science ®Google Scholar
• Woodhouse N, Wild JM, van Beek EJR, et al. Assessment of hyperpolarized 3He lung MRI for regional evaluation of interventional therapy: a pilot study in pediatric cystic fibrosis. J Magn Reson Imaging. 2009;30(5):981–988.
   PubMed Web of Science ®Google Scholar
• van Beek EJR, Hill C, Woodhouse N, et al. Assessment of lung disease in children with cystic fibrosis using hyperpolarized 3-Helium MRI: comparison with Shwachman score, Chrispin-Norman score and spirometry. Eur Radiol. 2007;17(4):1018–1024.
   PubMed Web of Science ®Google Scholar
• Walkup LL, Thomen RP, Akinyi TG, et al. Feasibility, tolerability and safety of pediatric hyperpolarized 129Xe magnetic resonance imaging in healthy volunteers and children with cystic fibrosis. Pediatr Radiol. 2016. doi:10.1007/s00247-016-3672-1. [Epub ahead of print]
   Web of Science ®Google Scholar
• Altes TA, Johnson M, Mugler JP 3rd, et al. The effect of ivacaftor, an investigational cftr potentiator, on hyperpolarized noble gas magnetic resonance imaging in subjects with cystic fibrosis who have the G551d-Cftr mutation. Am J Resp Crit Care Med. 2012;185:A2814.
   Google Scholar
• Grasemann H, Michler E, Wallot M, et al. Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol. 1997;24(3):173–177.
   PubMed Web of Science ®Google Scholar
• Grasemann H, Ratjen F. Nitric oxide and L-arginine deficiency in cystic fibrosis. Curr Pharm Des. 2012;18(5):726–736.
   PubMed Web of Science ®Google Scholar
• Ho LP, Innes JA, Greening AP. Exhaled nitric oxide is not elevated in the inflammatory airways diseases of cystic fibrosis and bronchiectasis. Eur Respir J. 1998;12(6):1290–1294.
   PubMed Web of Science ®Google Scholar
• Grasemann H, Knauer N, Buscher R, et al. Airway nitric oxide levels in cystic fibrosis patients are related to a polymorphism in the neuronal nitric oxide synthase gene. Am J Respir Crit Care Med. 2000;162(6):2172–2176.
   PubMed Web of Science ®Google Scholar
• Grasemann H, Lax H, Treseler JW, et al. Dornase alpha and exhaled NO in cystic fibrosis. Pediatr Pulmonol. 2004;38(5):379–385.
   PubMed Web of Science ®Google Scholar
• Zetterquist W, Marteus H, Kalm-Stephens P, et al. Oral bacteria–the missing link to ambiguous findings of exhaled nitrogen oxides in cystic fibrosis. Respir Med. 2009;103(2):187–193.
   PubMed Web of Science ®Google Scholar
• Jaffe A, Slade G, Rae J, et al. Exhaled nitric oxide increases following admission for intravenous antibiotics in children with cystic fibrosis. J Cyst Fibros. 2003;2(3):143–147.
   PubMedGoogle Scholar
• Grasemann H, Gonska T, Avolio J, et al. Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis. J Cyst Fibros. 2015;14(6):727–732.
   PubMed Web of Science ®Google Scholar
• Kotha K, Szczesniak RD, Naren AP, et al. Concentration of fractional excretion of nitric oxide (FENO): a potential airway biomarker of restored CFTR function. J Cyst Fibros. 2015;14(6):733–740.
   PubMed Web of Science ®Google Scholar
• Santini G, Mores N, Penas A, et al. Electronic nose and exhaled breath NMR-based metabolomics applications in airways disease. Curr Top Med Chem. 2016;16(14):1610–1630.
   PubMed Web of Science ®Google Scholar
• Montuschi P, Paris D, Melck D, et al. NMR spectroscopy metabolomic profiling of exhaled breath condensate in patients with stable and unstable cystic fibrosis. Thorax. 2012;67(3):222–228.
   PubMed Web of Science ®Google Scholar
• Montuschi P, Paris D, Montella S, et al. Nuclear magnetic resonance-based metabolomics discriminates primary ciliary dyskinesia from cystic fibrosis. Am J Respir Crit Care Med. 2014;190(2):229–233.
   PubMed Web of Science ®Google Scholar
• Tate S, MacGregor G, Davis M, et al. Airways in cystic fibrosis are acidified: detection by exhaled breath condensate. Thorax. 2002;57(11):926–929.
   PubMed Web of Science ®Google Scholar
• de Heer K, Kok MG, Fens N, et al. Detection of airway colonization by aspergillus fumigatus by use of electronic nose technology in patients with cystic fibrosis. J Clin Microbiol. 2016;54(3):569–575.
   PubMed Web of Science ®Google Scholar
• Joensen O, Paff T, Haarman EG, et al. Exhaled breath analysis using electronic nose in cystic fibrosis and primary ciliary dyskinesia patients with chronic pulmonary infections. PLoS One. 2014;9(12):e115584.
   PubMed Web of Science ®Google Scholar
• Vertex Pharmaceuticals Incorporated. Kalydeco physician label. 2015. Available from: http://pi.vrtx.com/files/uspi_ivacaftor.pdf
   Google Scholar
• U.S. Food and Drug Administration. FDA notification to the cystic fibrosis community on kalydeco (ivacaftor). 2012. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm316693.htm
   Google Scholar